myrwdРеальная клиническая практика: данные и доказательстваReal-World Data & Evidence2782-3784Publishing House OKI10.37489/2782-3784-myrwd-8UJOEUBmyrwd-11Research ArticleРЕГУЛЯТОРНАЯ СИСТЕМАREGULATORY SYSTEMКитайский опыт по использованию доказательств, полученных на основе данных реальной клинической практики в процессе разработки, исследования и оценки лекарственных препаратовChinese experience on using RWE to support drug research, development and evaluationhttps://orcid.org/0000-0002-1919-2909КолбинА. С.KolbinA. S.

Колбин Алексей Сергеевич, д. м. н., профессор, заведующий кафедрой клинической фармакологии и доказательной медицины; профессор кафедры фармакологии медицинского факультета Санкт-Петербургского государственного университета 

Санкт-Петербург

alex.kolbin@mail.ruhttps://orcid.org/0000-0002-2164-8290БелоусовД. Ю.BelousovD. Yu.

Белоусов Дмитрий Юрьевич, Генеральный директор 

Москва

Moscow

clinvest@mail.ruФГБОУ ВО «Первый Санкт-Петербургский государственный медицинский университет им академика И.П. Павлова» Министерства здравоохранения Российской ФедерацииРоссияFSBEI HE I.P. Pavlov SPbSMU MOH RussiaRussian FederationООО «Центр фармакоэкономических исследований»РоссияLLC “Center for Pharmacoeconomics Research”Russian Federation202215032022211727Copyright © Колбин А.С., Белоусов Д.Ю., 20222022Колбин А.С., Белоусов Д.Ю.Kolbin A.S., Belousov D.Y.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://www.myrwd.ru/jour/article/view/11

В статье описываются регуляторные подходы к сбору, анализу и использованию данных реальной клинической практики, которые применяются в Китае.

The article describes the regulatory approaches to the collection, analysis and usage of real-world data applied in China.

данные реальной клинической практикирегуляторные подходыкитайский опытreal-world dataregulatory approachesChinese experienceReferencesSun YX, Wei FF, Yang Y. Opportunities and Challenges in Using Real-World Evidence to Support Regulatory Decision Making for Drug and Medical Devices. Chinese Journal of Pharmacovigilance. 2017;(06):353–8.Sun YX, Wei FF, Yang Y. Opportunities and Challenges in Using Real-World Evidence to Support Regulatory Decision Making for Drug and Medical Devices. Chinese Journal of Pharmacovigilance. 2017;(06):353–8.Wu YL, Chen XY, Yang ZM, et al (Wu Jieping Medical Foundation, Chinese Thoracic Oncology Group). Guidance on Real World Research. 2018.Wu YL, Chen XY, Yang ZM, et al (Wu Jieping Medical Foundation, Chinese Thoracic Oncology Group). Guidance on Real World Research. 2018.General Office of the CPC Central Committee, General Office of the State Council. Opinions on Deepening the Evaluation, Review and Approval System Reform and Encouraging Innovation of Drugs and Medical Devices. 2017.General Office of the CPC Central Committee, General Office of the State Council. Opinions on Deepening the Evaluation, Review and Approval System Reform and Encouraging Innovation of Drugs and Medical Devices. 2017.ADAPTABLE Investigators. Aspirin Dosing: a Patient-Centric Trial Assessing Benefits and Long-Term Effectiveness (ADAPTABLE) study protocol. http://pcornet.org/wp-content/uploads/2015/06/ADAPTABLE-Protocol-Final-Draft-6-4-15_for-post_06-26-.pdf. Published June, 2015, 5.ADAPTABLE Investigators. Aspirin Dosing: a Patient-Centric Trial Assessing Benefits and Long-Term Effectiveness (ADAPTABLE) study protocol. http://pcornet.org/wp-content/uploads/2015/06/ADAPTABLE-Protocol-Final-Draft-6-4-15_for-post_06-26-.pdf. Published June, 2015, 5.Berger M, Daniel G, Frank K, et al. A frame work for regulatory use of real-world evidence. White paper prepared by the Duke Margolis Center for Health Policy. 2017, 6.Berger M, Daniel G, Frank K, et al. A frame work for regulatory use of real-world evidence. White paper prepared by the Duke Margolis Center for Health Policy. 2017, 6.Cave A, Kurz X, Arlett P. Real-world data for regulatory decision making: challenges and possible solutions for Europe. Clinical pharmacology and therapeutics. 2019;106(1):36.Cave A, Kurz X, Arlett P. Real-world data for regulatory decision making: challenges and possible solutions for Europe. Clinical pharmacology and therapeutics. 2019;106(1):36.Dreyer NA. Advancing a framework for regulatory use of real-world evidence: when real is reliable. Therapeutic innovation & regulatory science. 2018;52(3):362–8.Dreyer NA. Advancing a framework for regulatory use of real-world evidence: when real is reliable. Therapeutic innovation & regulatory science. 2018;52(3):362–8.Egger M, Moons KGM, Fletcher C, et al. GetReal: from efficacy in clinical trials to relative effectiveness in the real world. Research synthesis methods. 2016;7(3):278–81.Egger M, Moons KGM, Fletcher C, et al. GetReal: from efficacy in clinical trials to relative effectiveness in the real world. Research synthesis methods. 2016;7(3):278–81.Ford I, Norrie J. Pragmatic trials. N Engl J Med. 2016;375(5):454–63.Ford I, Norrie J. Pragmatic trials. N Engl J Med. 2016;375(5):454–63.Institute of Medicine 2009. Initial national priorities for comparative effectiveness research. Washington, DC: The National Academies Press. https://doi.org/10.17226/12648.Institute of Medicine 2009. Initial national priorities for comparative effectiveness research. Washington, DC: The National Academies Press. https://doi.org/10.17226/12648.James S. Importance of post-approval real-word evidence. European Heart Journal-Cardiovascular Pharmacotherapy. 2018;4(1):10–11.James S. Importance of post-approval real-word evidence. European Heart Journal-Cardiovascular Pharmacotherapy. 2018;4(1):10–11.Kohl S. Joint HMA/EMA task force on big data established. Eur J Hosp Pharm. 2017;24(3): 180–90.Kohl S. Joint HMA/EMA task force on big data established. Eur J Hosp Pharm. 2017;24(3): 180–90.Lash TL, Fox MP, Fink AK. Applying quantitative bias analysis to epidemiologic data[M]. Springer Science & Business Media, 2011.Lash TL, Fox MP, Fink AK. Applying quantitative bias analysis to epidemiologic data[M]. Springer Science & Business Media, 2011.Makady A, de Boer A, Hillege H, et al. What is real-world data? A review of definitions based on literature and stakeholder interviews. Value in health. 2017;20(7):858–65.Makady A, de Boer A, Hillege H, et al. What is real-world data? A review of definitions based on literature and stakeholder interviews. Value in health. 2017;20(7):858–65.Olariu E, Papageorgakopoulou C, Bovens SM, et al. Real world evidence in Europe: a snapshot of its current status. Value in Health. 2016;19(7):A498.Olariu E, Papageorgakopoulou C, Bovens SM, et al. Real world evidence in Europe: a snapshot of its current status. Value in Health. 2016;19(7):A498.Roland M, Torgerson DJ. Understanding controlled trials: What are pragmatic trials? BMJ. 1998;316(7127):285.Roland M, Torgerson DJ. Understanding controlled trials: What are pragmatic trials? BMJ. 1998;316(7127):285.Sherman RE, Anderson SA, Dal Pan GJ, et al. Real-world evidence — what is it and what can it tell us. N Engl J Med. 2016;375(23):2293–7.Sherman RE, Anderson SA, Dal Pan GJ, et al. Real-world evidence — what is it and what can it tell us. N Engl J Med. 2016;375(23):2293–7.Sugarman J, Califf RM. Ethics and regulatory complexities for pragmatic clinical trials. JAMA. 2014;311(23):2381–2.Sugarman J, Califf RM. Ethics and regulatory complexities for pragmatic clinical trials. JAMA. 2014;311(23):2381–2.US Food and Drug Administration. Framework for FDA’s real-world evidence program. December 2018. 2019.US Food and Drug Administration. Framework for FDA’s real-world evidence program. December 2018. 2019.Velentgas P, Dreyer NA, Nourjah P, Smith SR, Torchia MM, eds. Developing a Protocol for Observational Comparative Effectiveness Research: A User’s Guide. AHRQ Publication No. 12(13) — EHC099. Rockville, MD: Agency for Healthcare Research and Quality, January 2013. www.effectivehealthcare.ahrq.gov/Methods-OCER.cfm.Velentgas P, Dreyer NA, Nourjah P, Smith SR, Torchia MM, eds. Developing a Protocol for Observational Comparative Effectiveness Research: A User’s Guide. AHRQ Publication No. 12(13) — EHC099. Rockville, MD: Agency for Healthcare Research and Quality, January 2013. www.effectivehealthcare.ahrq.gov/Methods-OCER.cfm.Von Elm E, Altman DG, Egger M, et al. The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies. Annals of internal medicine. 2007;147(8):573–7.Von Elm E, Altman DG, Egger M, et al. The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies. Annals of internal medicine. 2007;147(8):573–7.

The authors declare that there are no conflicts of interest present.